NRX Pharmaceuticals (NRXP) Cost of Revenue (2025 - 2026)

NRX Pharmaceuticals' (NRXP) quarterly Cost of Revenue came in at $631000.0 in Q1 2026, up 54.66% on a QoQ basis from $408000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Cost of Revenue (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has 2 years of Cost of Revenue data on file, last reported at $631000.0 in Q1 2026.

On a quarterly basis, Cost of Revenue changed N/A year-over-year to $631000.0 in Q1 2026; TTM through Mar 2026 was $1.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $505000.0, changed N/A from the prior year.
Cost of Revenue for Q1 2026 stood at $631000.0, up from $408000.0 in the prior quarter.
Over the last five years, Cost of Revenue for NRXP reached as high as $631000.0 in Q1 2026 and fell as low as $97000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	167.22 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	392.80 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	296.00 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	145.00 Mn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	NRX Pharmaceuticals	117.34 Mn	110.64 Mn	437,000.00	631,000.00

Download Data